// App-Quantinova.ai

: Is Initial Dasatinib-Blinatumomab Therapy for Ph-Positive ALL in Adults Cost Effective?

Researchers

Presenter

  • Jacob D. Bitran

Principal Investigators

  • Edward Nabrinsky

  • Shams Bufalino

  • Phillip Knouse

  • Angel G. Galvez

Medical Centers

  • Advocate Lutheran General Hospital, Park Ridge, IL

  • Bone Marrow Transplantation Program, Advocate Lutheran General Hospital, Hematology and Oncology (IM), Park Ridge, IL

  • Bone Marrow Transplantation Program, Advocate Lutheran General Hospital, Park Ridge, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved